

PHARMACEUTICAL PREPARATION COMPRISING A RECEPTOR ANTAGONIST FOR
THE TREATMENT OF BLOOD COAGULATION DISORDERS
VERSION OF MARKED CLAIMS

1.(amended) A pharmaceutical preparation for the treatment of blood coagulation disorders containing at least one pro-protein of blood coagulation selected from the group consisting of factor VIII, von Willebrand factor (vWF) or factor V, and, in addition, a coagulation physiologically inert receptor binding competitor selected from the group consisting of RAP, a RAP mutant, a RAP analogue and the combination of tissue type plasminogen activator (tPA) and aprotinin.

2. (amended) A preparation according to claim 1, characterized in that said pro-protein is derived from a biological material selected from the group consisting of human plasma, a plasma fraction and a cell culture supernatant.

3. (amended) A preparation according to claim 1 [or 2], characterized in that it is provided as a set [containing] comprising

- c) said pro-protein of blood coagulation and
- d) said receptor binding competitor.

4. (amended) A preparation according to [any one of] claim[s] 1 [to 3], characterized in that said pro-protein of blood coagulation is factor VIII and said receptor binding competitor is a mixture of aprotinin and tPA.

5. (amended) A preparation according to [any one of] claim[s] 1 [to 3], characterized in that said pro-protein of blood coagulation is vWF and said receptor binding competitor is a mixture of aprotinin and tPA. •

7. (amended) [The use of a preparation according to any one of claims 1 to 5 for the preparation of a means to] A method of treating a patient suffering from

phenotypic coagulation factor deficiency, comprising the step of administering a composition according to claim 1 to said patient.

8. (amended) The method [use] according to claim 7, further comprising the step of selecting a [characterized in that said] patient who is vWF deficient.

10. (amended) The method of claim 7, wherein [use of a preparation according to claim 9 containing] said receptor binding competitor is a mixture of aprotinin and tPA.

11. (amended) The method of claim 7, wherein [use according to claim 9, characterized in that] said pro-protein is blood coagulation factor VIII.